**Meet the editor**

Professor Robert Amato is the Chief of the Oncology Division and a Professor at the University of Texas Medical School at Houston and Director of Oncology at the Memorial Hermann Cancer Center. He obtained his Doctor of Osteopathic Medicine from the University of North Texas before becoming a fellow in Medical Oncology at MD Anderson Cancer Center. Dr. Amato is one of

the world's leading experts in the treatment of genitourinary cancer. Early in his career, his research helped make testicular cancer a highly treatable disease. His current research focuses on molecular-targeted therapeutics, halting the progression of metastatic kidney and prostate cancers, the further development of immunotherapies, and determining how his studies may be used to treat genitourinary cancer.

Contents

**Preface IX** 

Chapter 1 **Molecular Pathogenesis** 

**of Renal Cell Carcinoma: A Review 3**  Israel Gomy and Wilson Araújo Silva Jr.

Chapter 3 **The VHL-HIF Signaling in Renal Cell Carcinoma:** 

**of Renal Cell Carcinoma: Overcoming** 

Michele Guida and Giuseppe Colucci

Chapter 5 **Steroid Receptors in Renal Cell Carcinoma 99**  Evgeny Yakirevich, Andres Matoso, David J. Morris and Murray B. Resnick

**the SCF Ubiquitin E3 Ligase in RCC:** 

Tomoaki Tanaka and Tatsuya Nakatani

Christudas Morais, David W. Johnson and Glenda C. Gobe

**Potential Approaches to the NEDD8 Pathway 127** 

**the Resistance Mechanisms to Antiangiogenic Agents 83** 

**Promises and Pitfalls 57** 

Chapter 4 **The Next Challenge in the Treatment** 

Chapter 6 **Anticancer Target Molecules Against** 

Chapter 7 **Oxidative Stress and Redox-Signaling in Renal Cell Cancer 137** 

Karen Block

Chapter 2 **Molecular Portrait of Clear Cell Renal Cell Carcinoma: An Integrative Analysis of Gene Expression and Genomic Copy Number Profiling 23**  Cristina Battaglia, Eleonora Mangano, Silvio Bicciato, Fabio Frascati, Simona Nuzzo, Valentina Tinaglia, Cristina Bianchi, Roberto A. Perego and Ingrid Cifola

**Part 1 Translational 1** 

### Contents

#### **Preface XIII**

#### **Part 1 Translational 1**


Contents VII

Chapter 18 **New Systemic Approaches in**

Thean Hsiang Tan, Judith Lees,

Chapter 19 **Sequential Use of Targeted Therapies (TT)**

Chapter 20 **Treatment of Renal Cell Carcinoma**

Mirjana Rajer

**Part 4 Case Reports 433** 

G. Procopio, E. Verzoni, R. Iacovelli, F. Gelsomino, M. Catanzaro and L. Mariani

**in Elderly and Frail Patients 417**

Ganesalingam Pranavan and Desmond Yip

**in Metastatic Renal Cell Cancer (mRCC): Overall Results of a Large Experience 407** 

Chapter 21 **Simultaneous Nephron-Sparing Surgery and Caesarian** 

**Section for the Treatment of Renal Cell Carcinoma in Pregnancy: Case Report and Review of the Literature 435** Ambrosi Pertia, Laurent Managadze and Archil Chkhotua

**the Treatment of Metastatic Renal Cell Carcinoma 369** 

#### **Part 2 Surgery 227**


#### **Part 3 Clinical 335**

	- **Part 4 Case Reports 433**

VI Contents

Chapter 8 **Biological Aspects in Renal Cell Carcinoma 167** 

and Luis Miguel Antón Aparicio

Chapter 9 **Immunotherapy of Renal Cell Carcinoma –**

Mehrnaz Asadi Gharabaghi

Chapter 11 **Laparoscopic Partial Nephrectomy – Current State of the Art 245**

**Part 2 Surgery 227**

Vanessa Medina Villaamil, Guadalupe Aparicio Gallego

Chapter 10 **Clinical Spectrum of Patients with Renal Cell Carcinoma 229** 

Paul D'Alessandro, Shawn Dason and Anil Kapoor

Chapter 12 **Gasless Single Port Surgery for Renal Cell Carcinoma: Minimum Incision Endoscopic Surgery 273**  Kazunori Kihara, Yasuhisa Fujii, Satoru Kawakami, Hitoshi Masuda, Fumitaka Koga, Kazutaka Saito, Noboru Numao, Yoh Matsuoka and Yasuyuki Sakai

> **Gland Involvement in Renal Cell Carcinoma Exhibiting Venous Vascular Extension 289**  Tetsuo Fujita, Masatsugu Iwamura, Shinji Kurosaka,

Chapter 13 **Prognostic Impact of Perirenal Fat or Adrenal** 

Chapter 14 **Health-Related Quality of Life After Radical** 

Chapter 15 **Management of Renal Cell**

**Part 3 Clinical 335** 

Ken-ichi Tabata, Kazumasa Matsumoto, Kazunari Yoshida and Shiro Baba

**Nephrectomy and Kidney Donation 299** 

**Carcinoma Metastasis of the Spine 311** Alessandro Gasbarrini, Christiano Esteves Simões,

**in Metastatic Renal Cell Carcinoma 361** 

Michele Cappuccio and Stefano Boriani

Chapter 16 **Prognostic Factors in Renal Cell Carcinoma:** 

Minna Kankuri-Tammilehto

Chapter 17 **Contemporary Management** 

Murat Lekili

Archil Chkhotua, Tinatin Pantsulaia and Laurent Managadze

**An Evaluation of T-Stage, Histopathological Grade, p53, Ki-67, COX-2, and Her-2 Expressions 337**

**From Antigen Identification to Patient Treatment 193** Heiko Schuster, Mathias Walzer and Stefan Stevanović

> Chapter 21 **Simultaneous Nephron-Sparing Surgery and Caesarian Section for the Treatment of Renal Cell Carcinoma in Pregnancy: Case Report and Review of the Literature 435**  Ambrosi Pertia, Laurent Managadze and Archil Chkhotua

Preface

for the future.

disease that are on the horizon.

cell cancer treatments and research.

Genitourinary cancers are a diverse and challenging set of neoplasms for physicians and scientists to diagnose and manage. The field of renal cell cancer has undergone a significant resurgence. This book is an attempt to summarize, collate, and display this rapidly changing field, which encompasses medicine, surgery, radiation oncology, basic science, pathology, radiology, and supportive care. This text represents an up-todate look at the issues and answers regarding present knowledge and innovative ideas

I have assembled a stellar faculty to highlight the latest information of an ever changing disease. This includes tumor biology, molecular biology, surgery techniques, radiation therapy, personal testimonies, and present and future treatments of the

This book is aimed at the clinician and scientist who has an interest in renal cell cancer. My goal is to produce a textbook that can be read and used by practicing physicians, whether they are academic or nonacademic. The second goal was to produce a textbook that basic scientists working in this diverse and divergent field would be able to reference and read as an authoritative source. And finally, the third goal was to interpret the field for trainees in surgery, medicine, radiation oncology, and pathology. My hope is that this book reflects the increasing knowledge within the field of renal

> Professor and Director, Division of Oncology, University of Texas Medical School/Memorial Hermann Cancer Center, Chief of the Division of Oncology,

**Robert J. Amato, D.O.**

USA

Memorial Hermann Hospital TMC,

## Preface

Genitourinary cancers are a diverse and challenging set of neoplasms for physicians and scientists to diagnose and manage. The field of renal cell cancer has undergone a significant resurgence. This book is an attempt to summarize, collate, and display this rapidly changing field, which encompasses medicine, surgery, radiation oncology, basic science, pathology, radiology, and supportive care. This text represents an up-todate look at the issues and answers regarding present knowledge and innovative ideas for the future.

I have assembled a stellar faculty to highlight the latest information of an ever changing disease. This includes tumor biology, molecular biology, surgery techniques, radiation therapy, personal testimonies, and present and future treatments of the disease that are on the horizon.

This book is aimed at the clinician and scientist who has an interest in renal cell cancer. My goal is to produce a textbook that can be read and used by practicing physicians, whether they are academic or nonacademic. The second goal was to produce a textbook that basic scientists working in this diverse and divergent field would be able to reference and read as an authoritative source. And finally, the third goal was to interpret the field for trainees in surgery, medicine, radiation oncology, and pathology. My hope is that this book reflects the increasing knowledge within the field of renal cell cancer treatments and research.

#### **Robert J. Amato, D.O.**

Professor and Director, Division of Oncology, University of Texas Medical School/Memorial Hermann Cancer Center, Chief of the Division of Oncology, Memorial Hermann Hospital TMC, USA

**Part 1** 

**Translational** 
